LEVOPROME
Pre-Launchlevomepromazine
NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Levomepromazine (Levoprome) is an injectable phenothiazine antipsychotic used to treat severe psychiatric conditions including schizophrenia, agitation, and resistant psychosis. It acts as a dopamine antagonist with additional serotonergic and alpha-adrenergic blocking properties. The drug is indicated for parenteral administration in acute and chronic psychiatric emergencies.
Pre-Launch
Pre-launch stage indicates early-phase commercial infrastructure building with focus on regulatory, medical affairs, and initial sales force planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Levoprome at pre-launch stage offers entry-level and mid-career opportunities in regulatory, medical affairs, and commercial infrastructure development. Professionals joining now will build launch capabilities and establish the commercial foundation for a niche psychiatric injectable.
Regulatory Affairs SpecialistMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.